Posted by Michael Wonder on 23 Jan 2024
Ensysce Biosciences announces FDA breakthrough therapy designation granted for PF614-MPAR
23 January 2024 - FDA acknowledges significant potential impact of MPAR's oral overdose protection.
Ensysce Biosciences today announced receipt of notice from the US FDA that it has granted breakthrough therapy designation for PF614-MPAR.
